Supplementary file 2 , which might be attributed to the change of plasma milieus. Thus, instant prediction, rather than long-term predication, may be available for predicting the IHR risk of penicillin. In summary, our study demonstrates, for the first time, that as an activator of the FXII-driven contact system, penicillin can lead to hypersensitivity reactions in rodent models, which can be hampered by icatibant, a B2R pharmacological inhibitor.
These findings not only warrant further exploration of the penicillin-driven contact system as a source of therapeutic targets for treatment of anaphylaxis triggered by penicillin, but also might bring more effective diagnosis options for the prediction of penicillin-induced fatal risk. The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.
Simons, F. International consensus on ICON anaphylaxis. World Allergy Organ. Google Scholar. Nakamura, T. Regulation of vascular permeability in anaphylaxis.
Liew, W. Anaphylaxis fatalities and admissions in Australia. Allergy Clin. PubMed Google Scholar. Anaphylaxis epidemiology in patients with and patients without asthma: A United Kingdom database review. Wood, R. Anaphylaxis in America: The prevalence and characteristics of anaphylaxis in the United States. Moreno, E. Romano, A. Antibiotic allergies in children and adults: From clinical symptoms to skin testing diagnosis. Renaudin, J. Severe drug-induced anaphylaxis: Analysis of cases recorded by the Allergy Vigilance Network from to Allergy 68 , — Neugut, A.
Anaphylaxis in the United States: An investigation into its epidemiology. Patterson, R. Idsoe, O. Nature and extent of penicillin side-reactions, with particular reference to fatalities from anaphylactic shock. World Health Organ. Trubiano, J. Penicillin allergy is not necessarily forever.
JAMA , 82—83 Hjortlund, J. Diagnosis of penicillin allergy revisited: The value of case history, skin testing, specific IgE and prolonged challenge. Macy, E. Penicillin allergy: Optimizing diagnostic protocols, public health implications, and future research needs. Arroliga, M. A pilot study of penicillin skin testing in patients with a history of penicillin allergy admitted to a medical ICU. Chest , — Safely diagnosing clinically significant penicillin allergy using only penicilloyl-poly-lysine, penicillin, and oral amoxicillin.
Gadde, J. Clinical experience with penicillin skin testing in a large inner-city STD clinic. JAMA , — Schmaier, A. Oschatz, C. Mast cells increase vascular permeability by heparin-initiated bradykinin formation in vivo. Immunity 34 , — Sala-Cunill, A. Plasma contact system activation drives anaphylaxis in severe mast cell-mediated allergic reactions. Bender, L. Factor XII-driven inflammatory reactions with implications for anaphylaxis.
Naudin, C. Factor XII contact activation. Gao, Y. Strait, R. Pathways of anaphylaxis in the mouse. Khodoun, M. Peanuts can contribute to anaphylactic shock by activating complement. Yang, W. Allergy Asthma Immunol. Yang, Y. McNeil, B. Identification of a mast-cell-specific receptor crucial for pseudo-allergic drug reactions.
Nature , — Kishimoto, T. Contaminated heparin associated with adverse clinical events and activation of the contact system. Kaplan, A. Pathways for bradykinin formation and inflammatory disease.
CAS Google Scholar. Ji, N. Anaphylaxis and mortality induced by treatment of mice with anti-VLA-4 antibody and pertussis toxin. Han, J. Bircher, A. Hypersensitivity from intravenous iron products.
Murphey, L. Metabolism of bradykinin In vivo in humans: Identification of BK as a stable plasma peptide metabolite. Pathak, M. Cell receptor and cofactor interactions of the contact activation system and factor XI. Lausanne 5 , 66 The plasma bradykinin-forming pathways and its interrelationships with complement. Han, Y. Normal range and genetic analysis of coagulation factor XII in the general Chinese population.
Han, E. Increased vascular permeability in C1 inhibitor-deficient mice mediated by the bradykinin type 2 receptor. Mutch, N. Immobilized transition metal ions stimulate contact activation and drive factor XII-mediated coagulation. Novel roles for factor XII-driven plasma contact activation system. Foster, T. Trends Microbiol. Johansson, S. A revised nomenclature for allergy. Allergy 56 , — Bradykinin-mediated angioedema. Pumphrey, R. Fatal anaphylaxis in the UK, — Novartis Found Symp. Anaphylaxis: Can we tell who is at risk of a fatal reaction?.
Poulos, L. Trends in hospitalizations for anaphylaxis, angioedema, and urticaria in Australia, — to — Lee, J. Anaphylaxis: Mechanisms and management. Allergy 41 , — The bradykinin-forming cascade: A historical perspective. Allergy , — Banerji, A. Hereditary angioedema: Classification, pathogenesis, and diagnosis.
Allergy Asthma Proc. Christie, G. Drug—protein conjugates-XIII. This task may be best accomplished during medication reconciliation, but evaluation of allergy is an ongoing process.
The majority of deaths from anaphylaxis result from respiratory failure followed by cardiovascular compromise [ 29 ]. Maintenance of the airway and cardiovascular system comprise the critical foundation of anaphylaxis management. Epinephrine should be administered immediately. Outside the healthcare setting, intramuscular epinephrine given in the anterior lateral thigh is the preferred route.
If intravenous access is available, a bolus of epinephrine 0. Fluid administration with large volumes of crystalloids should occur concurrently with vasopressor infusion when the response to epinephrine is not immediate and sustained. Secondary therapeutic modalities such as antihistamines and corticosteroids do not immediately support blood pressure or reduce inflammation, but are commonly included in anaphylaxis protocols.
Antihistamines are useful for preventing or blunting angioedema or urticaria associated with IgE-mediated drug reactions. Simultaneous treatment with both an H 1 and an H 2 antagonist is recommended over a single agent for anaphylaxis [ 30 ]. Corticosteroids have little value in the acute phase of anaphylaxis, but they have well-known anti-inflammatory properties and are frequently included in anaphylaxis treatment algorithms because of their utility in preventing delayed anaphylactic reactions.
Classical desensitization protocols are designed to treat type 1 IgE—mediated mast cell reactions [ 31 ]. The typical request for drug desensitization may better be described as induction of drug tolerance without an adverse reaction [ 32 ].
This term more accurately reflects the diverse mechanisms that may be responsible for a specific drug reaction including IgE-mediated, non-IgE-mediated, and non-immune-mediated processes [ 16 ].
If an IgE-mediated sensitivity is established and the need for the drug confirmed, a standard desensitization protocol can be initiated. The goal of this procedure is described by some as controlled anaphylaxis—that is, the drug is administered at a concentration and rate that will cause drug-specific IgE-armed mast cells to degranulate at low rates that do not precipitate a systemic reaction.
Serial doses of medication are gradually increased usually doubled for each administration often at to minute intervals , and the number of IgE receptors on the mast cells are suppressed, which deceases the sensitivity of the mast cell to the point where a full dose of drug can ultimately be safely given.
This defines a clinically tolerant state to the continued administration of the drug with little risk of a significant mast cell—mediated reaction during the course of therapy. Once desensitized, the patient usually does not react to administration of the drug for the duration of therapy. After that, sensitivity is assumed to have returned, and future therapeutic courses will require repeated desensitization protocols. In cases where IgE-mediated sensitivity cannot be confirmed but the patient history strongly suggests that an immediate hypersensitivity state exists, drug allergy is assumed and the patient is subjected to a standard desensitization protocol [ 16 ].
In contrast, for cases where the history suggests that IgE-mediated hypersensitivity is not responsible for a previous reaction, a graded challenge protocol can be instituted [ 32 ]. A graded challenge is not intended to induce drug tolerance, and is designed primarily to demonstrate that administration of a specific drug will not result in an immediate reaction. A patient who tolerates a graded challenge without reaction can then be considered nonallergic, with a risk of future reaction no greater than the population at large.
There is further consideration to interpreting the results of a graded challenge. If the mechanism responsible for the reaction is a non-IgE-mediated or non—immune mediated, although there may be no initial reaction after the graded challenge, a delayed reaction such as rash or other organ dysfunction may still occur.
This is why, in the initial assessment, establishing the temporal relationship between initial drug exposure and first appearance of adverse clinical event is so important. As newer and more accurate techniques are developed to identify specific mechanism of antibiotic sensitivity, more specific and effective protocols will be developed to induce drug tolerance in susceptible patients.
Before beginning a desensitization procedure, several considerations must be reviewed to limit any major complications. The best clinical setting should be determined office, medical ward, intensive care unit. The desensitization protocol should be reviewed with the pharmacist and nurse to ensure optimal creation of formulas and strict adherence to the schedule.
The pharmacist should be aware that a dose may have to be remixed in the event of a dose failure. Adequate personnel should be available during the desensitization with the expectation that the process may take several hours or longer. Vital signs and adverse reactions should be monitored before and after each incremental dose. Medications for anaphylaxis should be immediately available, and some protocols advocate scheduling diphenhydramine throughout the desensitization with epinephrine at the bedside, whereas others recommend an intravenous line, electrocardiography monitor, and spirometer.
An adverse reaction does not necessarily require stopping the desensitization protocol and may proceed by repeating the last tolerable dose and rechallenging. Patients missing a dose may have to be desensitized again.
A sample adaptable desensitization protocol is listed in Table 3 , and medication-specific desensitization protocols are listed in Table 4 [ 12 , 33—44 ]. Antibiotic allergy remains an important barrier in providing ideal care, and with fewer new antibiotics available on the market along with increasing antibiotic resistance, the chance of an allergy—treatment mismatch is increasing.
Many patients with declared allergy may be given that medication after differentiating between allergy and intolerance. When a true drug allergy is highly likely based on history and skin testing when available , desensitization protocols can be used to give the patient an antibiotic in the safest and most responsible manner possible.
Fully understanding the mechanisms of allergy and engaging specialists in treatment further reduces risk. Author contributions. Conception and design: D. Potential conflicts of interest. All authors: No reported conflicts. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
Google Scholar. Google Preview. Oxford University Press is a department of the University of Oxford. It furthers the University's objective of excellence in research, scholarship, and education by publishing worldwide. Sign In or Create an Account. Sign In. Advanced Search. Search Menu. Article Navigation. Close mobile search navigation Article Navigation. Volume Article Contents Abstract. Antibiotic Hypersensitivity Reactions and Approaches to Desensitization.
Legendre , Davey P. Oxford Academic. Christina A. Gailen D. Edwin Swiatlo. Cite Cite Davey P. Select Format Select format. Permissions Icon Permissions. Abstract Before initiating antibiotic therapy, drug hypersensitivity is an important consideration, and a common strategy is to avoid giving patients medications when a high likelihood of severe reactions exists.
Table 1. Classification of Immune-Mediated Hypersensitivity Reactions. Common Name. I Immediate-type hypersensitivity Antigen binding to membrane-bound IgE on mast cells, resulting in release of biogenic amines, arachidonic acid metabolites, and other vasoactive molecules.
III Soluble antigen-antibody complexes Deposition of antigen-antibody complexes formed in solution on solid substrates such as cells or tissues IV a Delayed-type hypersensitivity Antigen-specific T-lymphocyte activation. Open in new tab. Figure 1. Open in new tab Download slide. Figure 2. Table 2. Type of Reaction. Previously Sensitized Patients. Patients Not Previously Sensitized. Figure 4.
Table 3. Sample Desensitization Protocol a for a 1-g Final Dose. Strength, mg. Volume, mL. These conditions include:. You may experience side effects of penicillin — as happens with other medications — that are not an allergic reaction to the drug. Depending on the type of penicillin, common side effects may include mild nausea or diarrhea, headache, or vaginal itching. Signs or symptoms of an infection for which you are being treated — or unrelated symptoms — also may be mistaken as an allergic drug reaction.
See your doctor as soon as possible if you experience signs or symptoms of penicillin allergy. It's important to understand and discuss what is an allergic reaction, what is a typical side effect and what you can tolerate in taking a medication.
Call or emergency medical help if you experience signs of a severe reaction or suspected anaphylaxis after taking penicillin. Penicillin allergy occurs when your immune system becomes hypersensitive to the drug — mistakenly reacting to the drug as a harmful substance, as if it were a viral or bacterial infection.
Before the immune system can become sensitive to penicillin, you have to be exposed to the medication at least once. If and when your immune system misidentifies penicillin as a harmful substance, it develops an antibody to the drug. The next time you take the drug, these specific antibodies flag it and direct immune system attacks on the substance.
Chemicals released by this activity cause the signs and symptoms associated with an allergic reaction. Previous exposure to penicillin may not be obvious. Some evidence suggests that trace amounts of it in the food supply may be sufficient for a person's immune system to create an antibody to it. Penicillins belong to a class of antibacterial drugs called beta-lactam antibiotics. Although the mechanisms of the drugs vary, generally they fight infections by attacking the walls of bacterial cells.
In addition to penicillins, other beta-lactams more commonly associated with allergic reactions are a group called cephalosporins.
If you've had an allergic reaction to one type of penicillin, you may be — but are not necessarily — allergic to other types of penicillin or to some cephalosporins. While anyone can have an allergic reaction to penicillin, a few factors can increase your risk.
These include:.
0コメント